Brief Summary
The main purpose of this study is to assess the efficacy and safety of 3 dosethe amount of medication taken levels of Pirtobrutinib in participants with relapsed or refractory chronica long-lasting disease that changes slowly over time lymphocytic leukemia (CLL) or small lymphocytic lymphomacancers of the lymphatic system (SLL), who have received 1-3 lines of treatment including a covalent Bruton tyrosine kinase (BTK) inhibitor. The study is expected to last approximately 3 years.
Intervention / Treatment
- Drug: Pirtobrutinib
Inclusion Criteria:
- Have confirmed diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results of CLL/SLL as defined by these iwCLL 2018 criteria.
- Have received prior CLL/SLL treatment
- Have received at least 1, but not more than 3 lines of prior treatment for CLL/SLL
- Have received a covalent BTK inhibitor
- Have a requirement for therapy consistent with iwCLL 2018 criteria for initiation of therapy
- Capable of swallowing oral study medication.
- Have an Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group Performance Status (ECOG) score of 0 to 2.